Change in work productivity and activity impairment
Patients in the asciminib arm reported a reduction in their activity impairment (6.5% reduction in impairment, compared to a 1.0% reduction in patients in the bosutinib arm). The analysis of impairment at work was limited due to the low proportion of patients who reported they were currently working. Trends similar to the results of the MDASI-CML interference score analysis were noted in the changes in percent work time missed, impairment while working, and overall work impairment, with trends of differences between treatments favoring asciminib, although the magnitudes of those mean changes were not considered clinically meaningful based on a 15% threshold (Supplementary Table 